Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will present a company overview at the upcoming virtual H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022.
The presentation will be available on-demand beginning January 10, at 7:00 am ET to registered conference attendees and the public at: https://journey.ct.events/view/67b1dab2-8dd0-4f50-8291-86cf6c38ed3b, and subsequently on the Zomedica website at: https://investors.zomedica.com/events-presentations.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company offering diagnostic and therapeutic products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio of innovative diagnostics and medical devices are designed to improve both patient and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Investor Relations Contacts
PCG Advisory Group
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.646.823.8656
Last Trade: | US$0.13 |
Daily Change: | 0.0028 2.13 |
Daily Volume: | 9,226,574 |
Market Cap: | US$131.310M |
November 14, 2024 November 08, 2024 November 07, 2024 October 24, 2024 October 03, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB